Description: Arix Bioscience plc is a United Kingdom-based healthcare and life science company. The Company is a holding company that is focused on generating value from the development and commercialization of technologies and discoveries. Its principal activity is to source, finance and develop healthcare and life science businesses across the world. The Company focuses on acquiring interests in, and provide operational oversight to, healthcare and life science businesses with which it partners in the healthcare and life science sector. The Company holds interests in BioMotiv, OptiKira LLC, Autolus, Depixus SAS, Verona Pharma plc and Artios Pharma Ltd. The Company has agreements with universities in the United Kingdom, Europe and Australia, providing direct access to new technologies. It also has access to a range of research projects from the United States academic institutions. Its subsidiaries include Arix Bioscience Holdings Limited, Arix US Inc and Arthurian Life Sciences GP Limited.
Home Page: arixbioscience.com
ARIX Technical Analysis
Duke Street House
London,
W1K 6JL
United Kingdom
Phone:
44 20 7290 1050
Officers
| Name | Title |
|---|---|
| Mr. Robert Lyne | CEO, Gen. Counsel & Director |
| Ms. Nikki Edgar | Head of Fin. |
| Mr. Mark Chin M.B.A., M.S. | Managing Director |
| Dr. Emmanuel Lacroix M.B.A., Ph.D. | Venture Partner |
| Mr. Felix Breyer Ph.D. | Associate |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| GIC Sector: | Financials |
|---|---|
| GIC Group: | Diversified Financials |
| GIC Industry: | Capital Markets |
| GIC Sub-Industry: | Asset Management & Custody Banks |
| Forward PE: | 3.6969 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6102 |
| Price-to-Sales TTM: | 672.4499 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 7 |